Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on pediatric orthopedics, and its news flow reflects this specialization. Company announcements frequently cover revenue updates, financial guidance, and quarterly earnings, where OrthoPediatrics discusses performance across its trauma and deformity, scoliosis, and specialty bracing (OPSB) product lines, as well as metrics such as the number of children treated with its systems.
Readers following KIDS news can expect regular updates on financial results and outlook, including preliminary unaudited revenue releases, full quarterly earnings reports, and adjustments to annual guidance. These releases often highlight contributions from specific product categories, trends in domestic and international revenue, and management’s commentary on operational initiatives such as restructuring efforts and cost management.
OrthoPediatrics also issues news on product development and regulatory milestones. Recent examples include FDA approval of the 3P Pediatric Plating Platform Small-Mini System, additional FDA clearances within a single year, and EUMDR certification for spine, trauma, and deformity implants and instruments. The company reports on first clinical procedures with new systems, such as the VerteGlide Spinal Growth Guidance System for early onset scoliosis, and on portfolio expansions like new PediHip bracing products within OPSB.
In addition, KIDS news includes strategic and corporate updates, such as distribution partnerships (for example, with MY01 for Continuous Perfusion Sensing Technology), expansion of OPSB clinics and territories, participation in healthcare and investor conferences, and changes to the board of directors. Investors and observers who monitor this news stream gain insight into how OrthoPediatrics is evolving its pediatric orthopedic platform, broadening its product offering, and engaging with clinicians and the capital markets.
OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its first quarter 2025 financial results on May 7, 2025, after market close. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.
Investors can access both the live and archived webcast of the earnings call through the Events & Presentations section of the company's website at www.orthopediatrics.com. The webcast recording will remain available for at least 90 days following the event.
OrthoPediatrics (Nasdaq: KIDS) has announced the U.S. launch of the VerteGlide Spinal Growth Guidance System, marking their 80th system for treating pediatric musculoskeletal conditions. The system, recently FDA-cleared, is designed to treat Early Onset Scoliosis (EOS) in children under 10 years old who often experience pulmonary and digestive dysfunction.
The VerteGlide system aims to correct deformity while minimizing repeat surgeries until skeletal maturity. Initial surgeries are expected to begin at select children's centers during summer 2025. The technology was developed in partnership with pediatric orthopedic surgeons Dr. Richard McCarthy and Dr. Scott Luhmann, utilizing Shilla™ technology licensed from Medtronic.
OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's leadership team, including President & CEO Dave Bailey and COO/CFO Fred Hite, will engage in a fireside chat during the conference.
Investors and interested parties can access the audio webcast of the discussion through OrthoPediatrics' investor relations website at http://ir.orthopediatrics.com, with a replay option available after the event.
OrthoPediatrics (Nasdaq: KIDS) has been named one of the 2025 Best Places to Work in Indiana for the 9th time by the Indiana Chamber of Commerce. The pediatric orthopedics-focused company joins 150 other organizations from over 20 industries across the state in this 20th edition of the recognition program.
Company President & CEO David Bailey emphasized their commitment to fostering an engaging and inclusive culture, highlighting continuous investments in employee development and meaningful career experiences. The recognition reflects the company's success in building a positive workplace environment focused on helping children.
Indiana Chamber President Vanessa Green Sinders noted the program's importance in evaluating workplace culture amid intense talent competition. The final rankings will be revealed at an awards ceremony on April 30th, 2025, followed by publication in the Chamber's BizVoice® magazine.
OrthoPediatrics (Nasdaq: KIDS) has announced its partnership with the Crossroads Pediatric Device Consortium (CPDC), a multi-institutional initiative focused on accelerating pediatric medical device development. The consortium includes Purdue University's Weldon School of Biomedical Engineering, the Indiana University School of Medicine's Department of Pediatrics, and Cook Medical.
This collaboration aims to strengthen the consortium's capabilities in developing and commercializing pediatric medical devices, particularly in orthopedics. The partnership leverages OrthoPediatrics' specialized expertise in pediatric orthopedics to enhance the consortium's innovative potential.
The CPDC's distinctive model integrates major medical device companies to streamline product development, regulatory navigation, and commercialization processes, ensuring efficient transition of pediatric medical innovations from concept to market.
OrthoPediatrics (NASDAQ: KIDS) reported strong financial results for Q4 and full year 2024. The company achieved record annual revenue of $204.7 million, up 38% from 2023, with domestic revenue increasing 45% and international revenue growing 15%.
Q4 2024 highlights include total revenue of $52.7 million, a 40% increase year-over-year, and adjusted EBITDA of $3.0 million, more than double compared to Q4 2023. The company helped over 34,000 children in Q4 and approximately 138,000 for the full year.
Key segment performance for 2024:
- Trauma and Deformity revenue: $145.1 million (+36%)
- Scoliosis revenue: $55.2 million (+45%)
- Sports Medicine/Other: $4.4 million (+11%)
For 2025, OrthoPediatrics projects revenue between $235.0-242.0 million, representing 15-18% growth, and expects adjusted EBITDA of $15.0-17.0 million.
OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
Investors can access the conference call through a live and archived webcast available on the company's website at www.orthopediatrics.com in the Events & Presentations section of the Investors page. The webcast will remain available for replay for at least 90 days following the event.
OrthoPediatrics Corp. (NASDAQ: KIDS) has announced a distribution agreement with Thrive Orthopedics through its OrthoPediatrics Specialty Bracing (OPSB) division. The agreement covers three pediatric orthotic solutions:
1. The F3 Hero Pediatric AFO: A carbon fiber ankle foot orthosis for children with walking challenges due to cerebral palsy, spina bifida, or chemotherapy-related foot drop.
2. The TruStretch Pediatric Equinus Brace®: An above-the-knee brace for stretching gastroc-soleus muscles in children with equinus deformity.
3. The Thrive® Pediatric X-Glide Carbon Fiber Insoles: Available in rigid and flexible styles as lightweight gait training tools.
OrthoPediatrics (NASDAQ: KIDS) announced record preliminary unaudited revenue for 2024, reaching $204.7 million, a 38% increase from 2023's $148.7 million. The company's domestic revenue grew 45% to $161.1 million, while international revenue increased 16% to $43.6 million.
Fourth quarter 2024 revenue reached $52.7 million, up 40% year-over-year, with domestic revenue growing 52% to $42.9 million and international revenue rising 5% to $9.8 million. The company helped over 34,000 children in Q4 2024, surpassing 1.1 million children helped since inception.
For 2025, OrthoPediatrics projects revenue between $235-242 million (15-18% growth), with expected annual set deployment of $15 million and adjusted EBITDA of $15-17 million. The company highlighted strong performance in Trauma and Deformity, Scoliosis, and specialty bracing businesses.
OrthoPediatrics Corp. (KIDS) announced the expansion of its Specialty Bracing (OPSB) division into three new markets in Indiana, Colorado, and Florida. The OPSB division, launched in early 2024, aims to increase pediatric care access through new clinics and strategic acquisitions.
The company opened a new clinic in Indianapolis near Riley Children's Hospital and Peyton Manning Children's Hospital, established a new site within Nationwide Children's Hospital in Columbus, OH, acquired a clinic group in Colorado with plans for Denver area expansion, and acquired a clinic in Davie, Florida, serving as a foundation for statewide growth.
This expansion is part of OPSB's multi-year strategy to enhance access to non-operative pediatric orthopedic solutions through both greenfield clinics and strategic acquisitions, focusing on partnerships with pediatric orthopedic surgeons across different regions.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
